<\/p>\n
Lipaglyn<\/strong> je zna\u010dka saroglitazar<\/strong> (4 mg), du\u00e1ln\u00ed agonista PPAR-\u03b1\/\u03b3<\/strong> vyvinuto v Indii (schv\u00e1leno 2013). Je unik\u00e1tn\u00ed: p\u0159ev\u00e1\u017en\u011b agonista PPAR-\u03b1 (jako fibr\u00e1ty) s \u010d\u00e1ste\u010dnou agonizac\u00ed PPAR-\u03b3 (jako pioglitazon). Pou\u017e\u00edv\u00e1 se pro diabetickou dyslipid\u00e9mii<\/strong> (zv\u00fd\u0161en\u00e9 triglyceridy u diabetu 2. typu) a nealkoholick\u00e9 ztu\u010dn\u011bn\u00ed jater (NAFLD\/NASH)<\/strong> \u2014 schv\u00e1leno v Indii pro ob\u011b indikace. Sni\u017euje triglyceridy o 40\u201350%, zvy\u0161uje HDL, sni\u017euje HbA1c o ~0,5 bodu a zlep\u0161uje jatern\u00ed tuk a enzymy. Jedna tableta (4 mg) jednou denn\u011b p\u0159ed j\u00eddlem. Nezp\u016fsobuje hypoglyk\u00e9mii. Obecn\u011b dob\u0159e sn\u00e1\u0161en\u00e9 \u2014 m\u00edrn\u00e9 gastrointestin\u00e1ln\u00ed pot\u00ed\u017ee, vz\u00e1cn\u00e9 p\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze. Nen\u00ed n\u00e1hradou za statiny<\/strong> v prim\u00e1rn\u00ed l\u00e9\u010db\u011b lipid\u016f. Vyvarujte se u t\u011b\u017ek\u00e9ho jatern\u00edho po\u0161kozen\u00ed, t\u011bhotenstv\u00ed a zn\u00e1m\u00e9 p\u0159ecitliv\u011blosti.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Lipaglyn je peror\u00e1ln\u00ed du\u00e1ln\u00ed agonista PPAR-\u03b1\/\u03b3<\/strong> obsahuj\u00edc\u00ed saroglitazar<\/strong> (4 mg), vyvinut\u00fd spole\u010dnost\u00ed Zydus Cadila (Indie) a schv\u00e1len\u00fd v Indii v roce 2013. Dostupn\u00e9 v balen\u00edch po 30, 60, 90 nebo 180 tablet\u00e1ch. P\u0159edepisuje se na:<\/p>\n Saroglitazar je unik\u00e1tn\u00ed t\u00edm, \u017ee je prvn\u00edm dvojit\u00fdm agonistou PPAR-\u03b1\/\u03b3 na trhu. P\u0159edchoz\u00ed pokusy (muraglitazar, tesaglitazar) byly ukon\u010deny kv\u016fli bezpe\u010dnostn\u00edm obav\u00e1m; vyv\u00e1\u017een\u00fd profil saroglitazaru (p\u0159ev\u00e1\u017en\u011b \u03b1, \u010d\u00e1ste\u010dn\u011b \u03b3) se zd\u00e1 b\u00fdt bezpe\u010dn\u00fd.<\/p>\n Peroxisomov\u00e9 prolifer\u00e1torov\u011b aktivovan\u00e9 receptory (PPAR) jsou jadern\u00e9 receptory, kter\u00e9 reguluj\u00ed genovou expresi v metabolismu lipid\u016f a gluk\u00f3zy. Saroglitazar aktivuje dva z nich:<\/p>\n V\u00fdsledn\u00fd efekt je zlep\u0161en\u00ed obou<\/em> lipidn\u00ed profil a glykemickou kontrolu u diabetick\u00e9 dyslipid\u00e9mie v jedn\u00e9 tablet\u011b. D\u016fle\u017eit\u00e9 je, \u017ee proto\u017ee aktivace PPAR-\u03b3 je pouze \u010d\u00e1ste\u010dn\u00e1, p\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze a zadr\u017eov\u00e1n\u00ed tekutin pozorovan\u00e9 u pioglitazonu jsou mnohem m\u00e9n\u011b \u010dast\u00e9.<\/p>\n Standardn\u00ed d\u00e1vka:<\/strong> jednu tabletu 4 mg jednou denn\u011b, p\u0159ibli\u017en\u011b jednu hodinu p\u0159ed j\u00eddlem (r\u00e1no).<\/p>\n Saroglitazar je obecn\u011b dob\u0159e sn\u00e1\u0161en.<\/p>\n \u010cast\u00e9:<\/strong><\/p>\n M\u00e9n\u011b \u010dast\u00e9:<\/strong><\/p>\n \u017d\u00e1dn\u00fd jasn\u00fd sign\u00e1l srde\u010dn\u00edho selh\u00e1n\u00ed nebo rakoviny mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e (na rozd\u00edl od pioglitazonu). Dosud nejsou k dispozici data z v\u00fdsledkov\u00fdch studi\u00ed kardiovaskul\u00e1rn\u00edch p\u0159\u00edhod, ale dosavadn\u00ed omezen\u00e9 studie jsou uklid\u0148uj\u00edc\u00ed.<\/p>\n Skladujte Lipaglyn p\u0159i teplot\u011b do 30\u00b0C na such\u00e9m m\u00edst\u011b, v p\u016fvodn\u00edm blistru. Uchov\u00e1vejte mimo dosah d\u011bt\u00ed.<\/p>\n Oba jsou agonist\u00e9 PPAR, ale s odli\u0161nou selektivitou. Pioglitazon p\u016fsob\u00ed prim\u00e1rn\u011b na PPAR-\u03b3 (siln\u00fd senzibiliz\u00e1tor inzul\u00ednu, p\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze, zadr\u017eov\u00e1n\u00ed tekutin). Saroglitazar p\u016fsob\u00ed hlavn\u011b na PPAR-\u03b1 s \u010d\u00e1ste\u010dn\u00fdm<\/em> \u00fa\u010dinkem na PPAR-\u03b3 (siln\u00e9 sn\u00ed\u017een\u00ed triglycerid\u016f, m\u00edrn\u00e1 senzibilizace inzul\u00ednu, v\u00fdrazn\u011b men\u0161\u00ed p\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze a otoky). U pacient\u016f s diabetickou dyslipidemi\u00ed m\u00e1 saroglitazar siln\u011bj\u0161\u00ed \u00fa\u010dinek na lipidy; u \u010dist\u00e9 inzul\u00ednov\u00e9 rezistence s norm\u00e1ln\u00edmi lipidy se st\u00e1le \u010dast\u011bji pou\u017e\u00edv\u00e1 pioglitazon.<\/p>\n Ne \u2014 saroglitazar a statiny c\u00edl\u00ed na r\u016fzn\u00e9 lipidov\u00e9 abnormality. Statiny sni\u017euj\u00ed LDL-cholesterol (hlavn\u00ed aterogenn\u00ed lipid); saroglitazar sni\u017euje triglyceridy a zvy\u0161uje HDL. U diabetick\u00fdch pacient\u016f se sm\u00ed\u0161enou dyslipidemi\u00ed se obvykle pou\u017e\u00edvaj\u00ed spole\u010dn\u011b.<\/p>\n Ano \u2014 saroglitazar m\u00e1 schv\u00e1len\u00e9 indikace pro NAFLD\/NASH v Indii na z\u00e1klad\u011b indick\u00fdch klinick\u00fdch studi\u00ed, kter\u00e9 prok\u00e1zaly sn\u00ed\u017een\u00ed ALT, obsahu tuku v j\u00e1trech na MRI-PDFF a zlep\u0161en\u00ed marker\u016f fibr\u00f3zy. Je to jeden z m\u00e1la peror\u00e1ln\u00edch l\u00e9k\u016f s regula\u010dn\u00edm schv\u00e1len\u00edm pro NASH kdekoli na sv\u011bt\u011b.<\/p>\n Ne samostatn\u011b \u2014 saroglitazar nestimuluje uvol\u0148ov\u00e1n\u00ed inzul\u00ednu. Hypoglyk\u00e9mie se st\u00e1v\u00e1 probl\u00e9mem pouze v kombinaci se sulfonylureou, meglitinidem nebo inzul\u00ednem.<\/p>\n Saroglitazar je schv\u00e1len p\u0159edev\u0161\u00edm v Indii, s n\u011bkter\u00fdmi schv\u00e1len\u00edmi v Mexiku a n\u011bkolika dal\u0161\u00edch zem\u00edch. Dosud nen\u00ed schv\u00e1len v USA, EU, UK ani Austr\u00e1lii \u2014 tyto agentury je\u0161t\u011b nedokon\u010dily p\u0159ezkum. Klinicky byl l\u00e9k pou\u017eit u v\u00edce ne\u017e 2 milion\u016f pacient\u016f v Indii s dobr\u00fdm bezpe\u010dnostn\u00edm profilem.<\/p>\n Lipaglyn (4 mg) si m\u016f\u017eete objednat na MedsBase v balen\u00edch po 30, 60, 90 nebo 180 tablet\u00e1ch. Dod\u00e1v\u00e1me po cel\u00e9m sv\u011bt\u011b, s diskr\u00e9tn\u00edm balen\u00edm a origin\u00e1ln\u00edmi z\u00e1sobami od v\u00fdrobce certifikovan\u00e9ho WHO-GMP.<\/p>\n <\/p>\n Dal\u0161\u00ed produkty v Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n \u2705 Reguluje hladinu lipid\u016f Lipaglyn obsahuje Saroglitazar.<\/p>","protected":false},"featured_media":59204,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3230,3231],"product_tag":[4645,4646],"class_list":{"0":"post-59203","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-diabetes","9":"product_cat-diabetes-medication","10":"product_tag-lipaglyn","11":"product_tag-saroglitazar","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/59203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=59203"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/59204"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=59203"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=59203"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=59203"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=59203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
Co je Lipaglyn?<\/h2>\n
\n
Jak Lipaglyn funguje?<\/h2>\n
\n
D\u00e1vkov\u00e1n\u00ed a pod\u00e1n\u00ed<\/h2>\n
\n
Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n
\n
\n
Interakce s l\u00e9\u010divy<\/h2>\n
\n
Kdo by nem\u011bl u\u017e\u00edvat Lipaglyn?<\/h2>\n
\n
Skladov\u00e1n\u00ed<\/h2>\n
\u010casto kladen\u00e9 dotazy<\/h2>\n
Jak se saroglitazar li\u0161\u00ed od pioglitazonu?<\/h3>\n
M\u016f\u017ee Lipaglyn nahradit m\u016fj statin?<\/h3>\n
Pom\u00e1h\u00e1 Lipaglyn p\u0159i ztu\u010dn\u011bn\u00ed jater nebo NASH?<\/h3>\n
Zp\u016fsobuje Lipaglyn hypoglyk\u00e9mii?<\/h3>\n
Je Lipaglyn schv\u00e1len mimo Indii?<\/h3>\n
Kde si mohu koupit Lipaglyn online?<\/h3>\n
Souvisej\u00edc\u00ed l\u00e9ky na diabetes a lipidy<\/h2>\n
\n
Souvisej\u00edc\u00ed alternativy<\/h3>\n
\n
\n\u2705 Reguluje hladinu cukru v krvi
\n\u2705 Sni\u017euje kardiovaskul\u00e1rn\u00ed riziko
\n\u2705 Zlep\u0161uje citlivost na inzul\u00edn
\n\u2705 Zlep\u0161uje metabolick\u00e9 zdrav\u00ed<\/p>\n